Yahoo Finance Today's Research Reports on Trending Tickers: Cronos Group and Nektar Therapeutics
NEW YORK, NY / ACCESSWIRE / September 5, 2018 / Wall Street finished in the red on Tuesday as investors focused on the latest trade negotiations between the U.S. and Canada, potentially paving the way to a revised North American Free Trade Agreement. The Dow Jones Industrial Average was down 0.05 percent to close at 25,952.48, while the S&P 500 Index decreased 0.17 percent to close at 2,896.72. The Nasdaq Composite Index dropped 0.23 percent to close at 8,091.25.
“Markets will continue to watch for additional trade news as usual,” said chief investment officer at Stone Investment Partners, Bill Stone. “Last week started with the positive news of a bilateral Nafta trade deal with Mexico. The week ended without a deal with Canada, but negotiations will continue this week. The U.S. also indicated that tariffs on an additional $200 billion in Chinese goods will begin this Thursday with China likely to retaliate in kind,” Stone said.
RDI Initiates Coverage on:
Cronos Group Inc.
https://rdinvesting.com/news/?ticker=CRON
Nektar Therapeutics
https://rdinvesting.com/news/?ticker=NKTR
Cronos Group's stock jumped 12.85% Tuesday, to close the day at $11.15. The stock recorded a trading volume of 43,194,897 shares, which was above its three months average volume of 9,380,256 shares. In the last year, Cronos Group's shares have traded in a range of 5.12 - 12.89. The share price has gained 117.77% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $7.33 is above its 200-day moving average of $7.12. Shares of the company are trading at a Price to Earnings ratio of 1115.00. Shares of Cronos Group have gained roughly 90.27 percent in the past month and are up 46.33 percent year-to-date.
Access RDI's Cronos Group Inc. Research Report at:
https://rdinvesting.com/news/?ticker=CRON
On Tuesday, shares of Nektar Therapeutics recorded a trading volume of 2,016,213 shares, which was below the three months average volume of 3,979,907 shares. The stock ended the day 3.01% higher at $68.49. The share price has fallen 38.5% from its 52 week high with a 52 week trading range of 21.05 - 111.36. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $56.56 is below its 200-day moving average of $74.43. Shares of the company are trading at a Price to Earnings ratio of 12.74. Shares of Nektar Therapeutics have gained roughly 26.97 percent in the past month and are up 14.69 percent year-to-date.
Access RDI's Nektar Therapeutics Research Report at:
https://rdinvesting.com/news/?ticker=NKTR
Our Actionable Research on Cronos Group Inc. (NYSE:CRON) and Nektar Therapeutics (NASDAQ:NKTR) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Address:
Email:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: RDInvesting.com
https://www.accesswire.com/511340/Todays-Research-Reports-on-Trending-Tickers-Cronos-Group-and-Nektar-Therapeutics
